Antibodies comprising modified heavy constant regions

US10653791B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Nils Lonberg · Woodside, US
• Alan J. Korman · Piedmont, US
• Mark J. Selby · San Francisco, US
• Bryan C. BARNHART · San Francisco, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Mohan Srinivasan · Cupertino, US
• Karla A. HENNING · Milpitas, US
• Michelle Minhua HAN · Piedmont, US
• Ming Lei · Princeton, US
• Liang Schweizer · Shanghai, CN
• Sandra V. HATCHER · Fryeburg, US
• Arvind Rajpal · San Francisco, US

Key dates

• Filing date: Nov 19, 2015
• Grant date: May 19, 2020
• Expiry date: Aug 27, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.